Lilly rolls out a multi‑dose pen

Eli Lilly has started selling Zepbound in a multi-dose KwikPen, giving patients a four-week tirzepatide pen instead of a one-shot device. (prnewswire.com) Lilly said on February 23, 2026 that the single-patient KwikPen is available by prescription through LillyDirect, and HCPLive reported the pen contains a full month’s dose for adults with obesity. (prnewswire.com) (hcplive.com) The new format comes in 2.5 milligram, 5 milligram, 7.5 milligram, 10 milligram, 12.5 milligram, and 15 milligram strengths, and Lilly’s instructions say each pen contains four fixed weekly doses. (prnewswire.com) (pi.lilly.com) Tirzepatide is a once-weekly injection used with diet and exercise to help adults with obesity, or adults with overweight plus a related condition, lose weight and keep it off. Lilly also markets Zepbound for moderate-to-severe obstructive sleep apnea in adults with obesity. (zepbound.lilly.com 1) (zepbound.lilly.com 2) The packaging change lands after the United States Food and Drug Administration said in December 2024 that the tirzepatide shortage had been resolved, ending a stretch when supply shaped how patients got the drug. (wsgr.com) Lilly is now offering Zepbound in three delivery formats: a single-dose pen, a single-dose vial, and the four-dose KwikPen. Its prescriber materials tell clinicians to make sure patients are trained on the specific device they receive. (zepbound.lilly.com) (accessdata.fda.gov) Price and convenience are part of the pitch. Lilly said patients can get all doses in either the multi-dose KwikPen or the single-dose vial at the same self-pay starting price of $299 through LillyDirect. (prnewswire.com) The pen does not change Zepbound’s core safety warnings. The prescribing information still carries a boxed warning about thyroid C-cell tumors seen in rats, and it says the drug is contraindicated for patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. (pi.lilly.com) For Lilly, the launch is less about a new medicine than a new way to package one of its biggest obesity drugs as the market shifts from pure supply constraints to format, access, and refill convenience. (hcplive.com) (pharmaceuticalcommerce.com)